US Medtechs Won't Rest On Laurels After Excise Tax Victory
In the polarized environment of Washington DC, the US medtech industry was becoming increasingly concerned as 2017 turned to 2018 that the medical device sales tax would be reinstated after a two-year suspension. AdvaMed chairman Nadim Yared tells In Vivo about the efforts and lobbying that got Congressmen onside just in time – but the battle doesn’t stop there.
You may also be interested in...
Bill Murray is stepping down as CEO of the Medical Device Innovation Consortium on Feb. 2, but he will be helping the group during the leadership transition period, and says he's excited about several long-term projects, including one designed to help better understand the evidence requirements sponsors should consider in pre-market trials to satisfy Medicare requirements. Murray spoke to Medtech Insight; read about it and listen to the podcast interview.
The US Centers for Medicare and Medicaid Services has withdrawn efforts on a proposed rule to offer faster Medicare reimbursement to novel devices, but the agency still plans to work on different approaches to provide "timely patient access" to device innovations, a spokeswoman said. AdvaMed says it is disappointed by CMS's decision to withdraw the rule after a 10-month review by the Office of Management and Budget.
There can be no such thing as a COVID dividend, but the renewed digital push and momentum for health system change perhaps come closest.